Alcohol septal ablation for the treatment of hypertrophic obstructive cardiomyopathy: A multicenter north american registry

Sherif F. Nagueh, Bertron M. Groves, Leonard Schwartz, Karen M. Smith, Andrew Wang, Richard G. Bach, Christopher Nielsen, Ferdinand Leya, John M. Buergler, Steven K. Rowe, Anna Woo, Yolanda Munoz Maldonado, William H. Spencer

Research output: Contribution to journalArticlepeer-review

120 Scopus citations

Abstract

Objectives: The purpose of the study is to identify the predictors of clinical outcome (mortality and survival without repeat septal reduction procedures) of alcohol septal ablation for the treatment of patients with hypertrophic obstructive cardiomyopathy. Background: Alcohol septal ablation is used for treatment of medically refractory hypertrophic obstructive cardiomyopathy patients with severe outflow tract obstruction. The existing literature is limited to single-center results, and predictors of clinical outcome after ablation have not been determined. Registry results can add important data. Methods: Hypertrophic obstructive cardiomyopathy patients (N = 874) who underwent alcohol septal ablation were enrolled. The majority (64%) had severe obstruction at rest, and the remaining had provocable obstruction. Before ablation, patients had severe dyspnea (New York Heart Association [NYHA] functional class III or IV: 78%) and/or severe angina (Canadian Cardiovascular Society angina class III or IV: 43%). Results: Significant improvement (p < 0.01) occurred after ablation (∼5% in NYHA functional classes III and IV, and 8 patients in Canadian Cardiovascular Society angina class III). There were 81 deaths, and survival estimates at 1, 5, and 9 years were 97%, 86%, and 74%, respectively. Left anterior descending artery dissections occurred in 8 patients and arrhythmias in 133 patients. A lower ejection fraction at baseline, a smaller number of septal arteries injected with ethanol, a larger number of ablation procedures per patient, a higher septal thickness post-ablation, and the use beta-blockers post-ablation predicted mortality. Conclusions: Variables that predict mortality after ablation, include baseline ejection fraction and NYHA functional class, the number of septal arteries injected with ethanol, post-ablation septal thickness, beta-blocker use, and the number of ablation procedures.

Original languageEnglish (US)
Pages (from-to)2322-2328
Number of pages7
JournalJournal of the American College of Cardiology
Volume58
Issue number22
DOIs
StatePublished - Nov 22 2011

Keywords

  • alcohol septal ablation
  • cardiomyopathy
  • hypertrophic

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Alcohol septal ablation for the treatment of hypertrophic obstructive cardiomyopathy: A multicenter north american registry'. Together they form a unique fingerprint.

Cite this